Latterell Venture Partners

Latterell Venture Partners

FinSMEs

Viracta Therapeutics Closes Series D Financing

the home of AI info

Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th ...

$65,000,000 Undisclosed
DealStreetAsia

HK’s Ally Bridge Group leads $65m financing for US-based Pulmonx

PE HUB

VC-backed Aptinyx goes public

Stock markets Funding
$70,000,000 Venture capital (Series B)
PE HUB , Venture Funding News

| Aptinyx lands $70 mln Series B

$18,400,000 Venture capital (Series B)
FierceBiotech

Viracta nabs $18.4M, Soon-Shiong as vice chair in Series B

$65,000,000 Venture capital (Series A)
biospace , FinSMEs

Naurex Spinout Aptinyx Banks 65 Million Series A to Advance Therapies for Neurological Disorders

Science Funding Health